Zevra Therapeutics (ZVRA) Operating Margin (2016 - 2025)
Historic Operating Margin for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to 15.87%.
- Zevra Therapeutics' Operating Margin rose 7538700.0% to 15.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 103.86%, marking a year-over-year increase of 2502800.0%. This contributed to the annual value of 368.47% for FY2024, which is 1878400.0% down from last year.
- According to the latest figures from Q3 2025, Zevra Therapeutics' Operating Margin is 15.87%, which was up 7538700.0% from 274.28% recorded in Q2 2025.
- Zevra Therapeutics' Operating Margin's 5-year high stood at 57.44% during Q1 2021, with a 5-year trough of 1908.85% in Q2 2022.
- In the last 5 years, Zevra Therapeutics' Operating Margin had a median value of 128.34% in 2024 and averaged 324.71%.
- In the last 5 years, Zevra Therapeutics' Operating Margin crashed by -19575100bps in 2022 and then soared by 18350300bps in 2023.
- Quarter analysis of 5 years shows Zevra Therapeutics' Operating Margin stood at 110.07% in 2021, then plummeted by -311bps to 452.13% in 2022, then soared by 74bps to 117.31% in 2023, then decreased by -9bps to 128.34% in 2024, then soared by 112bps to 15.87% in 2025.
- Its Operating Margin was 15.87% in Q3 2025, compared to 274.28% in Q2 2025 and 26.28% in Q1 2025.